José Van Der Heyden

Journal Article
A1
open access

Rapid and effective generation of nanobody based CARs using PCR and Gibson Assembly

Stijn De Munter (UGent) , Alexander Van Parys (UGent) , Layla Bral, Joline Ingels (UGent) , Glenn Goetgeluk (UGent) , Sarah Bonte (UGent) , Melissa Pille (UGent) , Lore Billiet (UGent) , Karin Weening (UGent) , Annick Verhee (UGent) , et al.

(2020) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 21(3).

Add to list

Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Franciane Paul, Genevieve Garcin, Stefaan De Koker (UGent) , Alexander Van Parys (UGent) , Thomas Wüest (UGent) , Sarah Gerlo (UGent) , José Van Der Heyden (UGent) , Yan Bordat, et al.

(2018) CANCER RESEARCH. 78(2). p.463-474

Add to list

Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma

Ahmet Krasniqi, Matthias D'Huyvetter, Catarina Xavier, Kevin Van der Jeught, Serge Muyldermans, José Van Der Heyden (UGent) , Tony Lahoutte, Jan Tavernier (UGent) and Nick Devoogdt

(2017) MOLECULAR CANCER THERAPEUTICS. 16(12). p.2828-2839

Add to list

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Geneviève Garcin, Jennyfer Bultinck (UGent) , Franciane Paul, Sarah Gerlo (UGent) , José Van Der Heyden (UGent) , Yann Bordat, Dominiek Catteeuw (UGent) , Lode De Cauwer (UGent) , et al.

(2017) ONCOIMMUNOLOGY. 7(3).

Add to list

Journal Article
A1
open access

TYK2-induced phosphorylation of Y640 suppresses STAT3 transcriptional activity

Raffaele Mori, Joris Wauman (UGent) , Laura Icardi (UGent) , José Van Der Heyden (UGent) , Lode De Cauwer (UGent) , Frank Peelman (UGent) , Karolien De Bosscher (UGent) and Jan Tavernier (UGent)

(2017) SCIENTIFIC REPORTS. 7.

Academic Bibliography

José Van Der Heyden

Rapid and effective generation of nanobody based CARs using PCR and Gibson Assembly

Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments

Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

TYK2-induced phosphorylation of Y640 suppresses STAT3 transcriptional activity

Contents

Support

Contact